Related Experiment Video
Updated: Jul 5, 2025

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation
Published on: August 23, 2018
NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and
Zhongting Mei1, Zhihua Shen2,3, Jiaying Pu2,3
1Department of Pharmacology, (The State-Province Key Laboratories of Biomedicine Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China.
Abstract:
The dynamic changes of RNA N6-methyladenosine (m6A) during cancer progression participate in various cellular processes. However, less is known about a possible direct connection between upstream regulator and m6A modification, and therefore affects oncogenic progression. Here, we have identified that a key enzyme in N4-acetylcytidine (ac4C) acetylation NAT10 is highly expressed in human osteosarcoma tissues, and its knockdown enhanced m6A contents and significantly suppressed osteosarcoma cell growth, migration and invasion. Further results revealed that NAT10 silence inhibits mRNA stability and translation of m6A reader protein YTHDC1, and displayed an increase in glucose uptake, a decrease in lactate production and pyruvate content. YTHDC1 recognizes differential m6A sites on key enzymes of glycolysis phosphofructokinase (PFKM) and lactate dehydrogenase A (LDHA) mRNAs, which suppress glycolysis pathway by increasing mRNA stability of them in an m6A methylation-dependent manner. YTHDC1 partially abrogated the inhibitory effect caused by NAT10 knockdown in tumor models in vivo, lentiviral overexpression of YTHDC1 partially restored the reduced stability of YTHDC1 caused by lentiviral depleting NAT10 at the cellular level. Altogether, we found ac4C driven RNA m6A modification can positively regulate the glycolysis of cancer cells and reveals a previously unrecognized signaling axis of NAT10/ac4C-YTHDC1/m6A-LDHA/PFKM in osteosarcoma. Video Abstract.
Insights
The enzyme NAT10 regulates RNA N4-acetylcytidine (ac4C) modification, impacting cancer progression. Inhibiting NAT10 enhances RNA N6-methyladenosine (m6A) levels, suppressing osteosarcoma growth and glycolysis.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Dynamic RNA modifications like m6A are crucial in cancer, but upstream regulators remain underexplored.
- The role of N4-acetylcytidine (ac4C) acetylation enzyme NAT10 in osteosarcoma and its link to m6A modification are investigated.
Discussion:
- NAT10 knockdown increases m6A levels, suppressing osteosarcoma cell proliferation, migration, and invasion.
- NAT10 regulates the stability and translation of the m6A reader protein YTHDC1.
- YTHDC1 influences glycolysis by recognizing m6A sites on PFKM and LDHA mRNAs, affecting their stability.
Key Insights:
- A novel signaling axis: NAT10/ac4C-YTHDC1/m6A-LDHA/PFKM positively regulates cancer cell glycolysis.
- NAT10 inhibition suppresses osteosarcoma progression by modulating m6A-dependent glycolysis.
- YTHDC1 partially rescues NAT10 knockdown effects, confirming its role in the pathway.
Outlook:
- Targeting the NAT10/ac4C-YTHDC1 axis offers potential therapeutic strategies for osteosarcoma.
- Further research can elucidate the precise mechanisms of ac4C and m6A crosstalk in cancer.
- Exploring YTHDC1's role in other cancers could reveal broader therapeutic applications.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Abnormal Proliferation
Spreading of Chromatin Modifications
Writers
The writer...
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...

